2-Oxo-3-hydroxy-LSD
| Clinical data | |
|---|---|
| Other names | 2-Oxy-3-hydroxy-LSD; OH-LSD; O-H-LSD; 2-Oxo-3-OH-LSD; 2-Oxo-3-hydroxy-2,3-dihydro-LSD; 2-Oxo-3-hydroxylysergide; 2-Oxo-3-hydroxylysergic acid diethylamide; N,N-Diethyl-2,3-dihydro-2-oxo-3-hydroxylysergamide; N,N-Diethyl-3-hydroxy-6-methyl-2-oxo-9,10-didehydro-2,3-dihydroergoline-8β-carboxamide |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H25N3O3 |
| Molar mass | 355.438 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2-Oxo-3-hydroxy-LSD, or 2-oxy-3-hydroxy-LSD, also known as O-H-LSD or OH-LSD, as well as more fully as 2-oxo-3-hydroxy-2,3-dihydro-LSD, is a lysergamide and the major metabolite of the psychedelic drug lysergic acid diethylamide (LSD). LSD is eliminated 13% as O-H-LSD in urine within 24 hours and urinary concentrations of O-H-LSD are 4 to 40 times those of LSD in humans.
The specific enzymes responsible for the formation of O-H-LSD from LSD are unclear. However, subsequent research found involvement of several cytochrome P450 enzymes. O-H-LSD is thought to form from other LSD metabolites like 2-oxo-LSD and 3-hydroxy-LSD.
It is unknown whether O-H-LSD is pharmacologically active or produces hallucinogenic effects. However, O-H-LSD showed profoundly reduced albeit still detectable activity at the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, compared to LSD in vitro.
O-H-LSD was first described in the scientific literature by at least the 1990s. It started being sold online as an analytical standard by 2024.